Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 50,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 3,318 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 3,318 · Balance 3,318 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 22,304 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 7,684 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.17 · Expires 2030-08-13 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 36,364 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 96,975 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001193125-26-276163 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 3,318 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267634 · ownership.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,318 Underlying: Common Stock · 3,318 shares Expires 2036-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267634 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000950170-25-088486 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085475 · ownership.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,413 Underlying: Common Stock · 2,413 shares Expires 2035-06-09 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 62,728 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085475 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,728 Underlying: Common Stock · 62,728 shares Expires 2035-06-09 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,736 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069887 · ownership.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,736 Underlying: Common Stock · 1,736 shares Expires 2034-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 40,282 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069887 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,282 Underlying: Common Stock · 40,282 shares Expires 2034-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:12 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right To Buy) · Derivative | 22,500 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0000950170-24-064211 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-05-20 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,966 | Not disclosed Strike: $72.74 | Not disclosed |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · derivative · entry 8 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,966 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,174 | Not disclosed Strike: $82.25 | Not disclosed |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · derivative · entry 7 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,174 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,684 | Not disclosed Strike: $85.12 | Not disclosed |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · derivative · entry 6 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,684 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,547 | Not disclosed Strike: $9.17 | Not disclosed |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · derivative · entry 5 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,547 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,790 | Not disclosed Strike: $16.82 | Not disclosed |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · derivative · entry 4 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,790 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,089 | Not disclosed Strike: $17.08 | Not disclosed |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · derivative · entry 3 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,089 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerCommon Stock | 8,111 | $19.00 | $154,109.00 |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · nonDerivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:44 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | OtherCommon Stock | 22,304 | $19.00 | $423,776.00 |
DisclosureSEC source: 0001104659-23-117105 · tm2330435-14_4seq1.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 915 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031786 · ownership.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915 Underlying: Common Stock · 915 shares Expires 2033-06-29 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 21,222 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031786 · ownership.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222 Underlying: Common Stock · 21,222 shares Expires 2033-06-29 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:38 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,547 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001104659-23-064840 · tm2317083-3_4seq1.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,547 Underlying: Common Stock · 12,547 shares Expires 2033-05-24 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:38 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 8,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064840 · tm2317083-3_4seq1.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,415 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2023 Filed May 25, 2023 23:37 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001610717-23-000071 · form4.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| April 12, 2023 Filed Oct 22, 2024 00:22 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 509 | $10.13 | $5,156.17 |
DisclosureSEC source: 0000950170-24-116048 · ownership.xml · nonDerivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 922 F1 · kind: The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person. The Reporting Person only recently become aware of these transactions. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021637 · doc4.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,319 Underlying: Common Stock · 2,319 shares Expires 2032-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 53,812 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021637 · doc4.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,812 Underlying: Common Stock · 53,812 shares Expires 2032-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:17 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,790 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001104659-22-065906 · tm2217184-3_4seq1.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,790 Underlying: Common Stock · 12,790 shares Expires 2032-05-25 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:17 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-065906 · tm2217184-3_4seq1.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,304 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2022 Filed May 25, 2022 23:02 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001567619-22-011720 · doc1.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:38 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 96,975 | $5.92 Strike: $3.58 | $574,092.00 |
DisclosureSEC source: 0001104659-21-136405 · tm2131118-6_4seq1.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 96,975 shares Expires 2031-05-12 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:38 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 36,364 | $5.33 Strike: $4.17 | $193,820.12 |
DisclosureSEC source: 0001104659-21-136405 · tm2131118-6_4seq1.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 36,364 shares Expires 2030-08-13 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 583 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023011 · doc4.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583 Underlying: Common Stock · 583 shares Expires 2031-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 13,534 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023011 · doc4.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,534 Underlying: Common Stock · 13,534 shares Expires 2031-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,089 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001104659-21-075220 · tm2118118-7_4seq1.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,089 Underlying: Common Stock · 12,089 shares Expires 2031-05-27 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-075220 · tm2118118-7_4seq1.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,567 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001567619-21-010747 · doc1.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-16 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:16 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 96,975 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001593968-21-001314 · primary_01.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,975 Underlying: Common stock · 96,975 shares Expires 2031-05-12 F1 · derivative.exercise_date: The stock option vests in full on the first anniversary of the grant date, or May 12, 2022 Read SEC document |
| May 03, 2021 Filed Oct 22, 2024 00:22 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 413 | $12.81 | $5,290.53 |
DisclosureSEC source: 0000950170-24-116048 · ownership.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413 F1 · kind: The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person. The Reporting Person only recently become aware of these transactions. Read SEC document |
| August 13, 2020 Filed Aug 13, 2020 17:19 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 36,364 | $4.17 Strike: $4.17 | $151,637.88 |
DisclosureSEC source: 0001593968-20-001745 · primary_01.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,364 Underlying: Common stock, $0.001 par value · 36,364 shares Expires 2030-08-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from August 13, 2020, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:48 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 26,503 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016183 · doc4.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,503 Underlying: Common Stock · 26,503 shares Expires 2030-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,966 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0001104659-20-068534 · tm2021501d5_4.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 Underlying: Common Stock · 2,966 shares Expires 2030-05-28 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-068534 · tm2021501d5_4.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,538 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 22:17 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 24,264 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0000899243-20-001261 · doc4.xml · derivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,264 Underlying: Common Stock · 24,264 shares Expires 2030-01-12 F1 · derivative.exercise_date: Exercisable in equal annual installments over three years of continuous service to the Issuer after January 13, 2020. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,174 | $0.00 Strike: $82.25 | $0.00 |
DisclosureSEC source: 0001144204-19-031958 · tv524024_4.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2029-06-20 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031958 · tv524024_4.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,943 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 7,684 | $0.00 Strike: $85.12 | $0.00 |
DisclosureSEC source: 0001144204-18-035418 · tv496985_4.xml · derivative · entry 2 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,684 Underlying: Common Stock · 7,684 shares Expires 2028-06-20 F2 · derivative.exercise_date: 1/3rd of the shares subject to the award shall vest and become exercisable on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 24, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035418 · tv496985_4.xml · nonDerivative · entry 1 Miller-Rich Nancy · CIK 0001735084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,373 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/3rd of the shares subject to the award shall vest on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.